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Available online 12 October 2016Background: The primary aim of our study was to evaluate the safety and potential toxicity of gemcitabine com-
bined with microbubbles under sonication in inoperable pancreatic cancer patients. The secondary aim was to
evaluate a novel image-guided microbubble-based therapy, based on commercially available technology, to-
wards improving chemotherapeutic efﬁcacy, preserving patient performance status, and prolonging survival.
Methods: Ten patients were enrolled and treated in this Phase I clinical trial. Gemcitabine was infused intrave-
nously over 30 min. Subsequently, patients were treated using a commercial clinical ultrasound scanner for
31.5 min. SonoVue®was injected intravenously (0.5 ml followed by 5 ml saline every 3.5 min) during the ultra-
sound treatment with the aim of inducing sonoporation, thus enhancing therapeutic efﬁcacy.
Results: The combined therapeutic regimen did not induce any additional toxicity or increased frequency of side
effects when compared to gemcitabine chemotherapy alone (historical controls). Combination treated patients
(n = 10) tolerated an increased number of gemcitabine cycles compared with historical controls (n= 63 pa-
tients; average of 8.3 ± 6.0 cycles, versus 13.8 ± 5.6 cycles, p = 0.008, unpaired t-test). In ﬁve patients, the
maximum tumour diameter was decreased from the ﬁrst to last treatment. The median survival in our patients
(n= 10) was also increased from 8.9 months to 17.6 months (p= 0.011).
Conclusions: It is possible to combine ultrasound, microbubbles, and chemotherapy in a clinical setting using
commercially available equipment with no additional toxicities. This combined treatmentmay improve the clin-
ical efﬁcacy of gemcitabine, prolong the quality of life, and extend survival in patients with pancreatic ductal
adenocarcinoma.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Clinical trial1. Introduction
A diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries one
of the most dismal prognoses in all of medicine. Currently the 4th mostaukeland University Hospital,
. Dimcevski).
. This is an open access article underlethal cancer in the western world, it has an average 5-year survival of
approximately 5% and is predictedwithin the decade to become the sec-
ond greatest cause of cancer death [1]. Surgery provides the only possi-
bility for cure, however N85% of newly diagnosed pancreatic tumours
are considered unresectable due to locally advanced disease with en-
casement of large blood vessels or metastasis. Furthermore, the preva-
lence of extreme desmoplasia generally renders the disease resistant
to chemo-radiative approaches [2]. Untreated, locally advanced PDAC
patients have a median survival of 6–10 months and 3–5 months forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinico-pathological characteristics of all pancreatic cancer patients. There was no statisti-
cally signiﬁcant difference between the sonoporation treated cohort and historical control
group in age, body mass index and blood chemistry. CA19-9 was not recorded in the his-
torical control cohort.
Variables (unit)
Sonoporation
(n = 10)
Control
(n = 63)
Start of treatment End of treatment Start of treatment
Age (years) 58.8 (±9.8) 59.5 (±10) 64.8 (±14.0)
Gender (%)
(male/female)
30/70 54/46
Body Mass Index
(kg/m2)
23.7 (±4.3) 23.9 (±5.1) 22.9 (±3.05)
ECOG performance
status (%)
0 50 10 71
1 50 80 29
2 0 10
Histological type Adenocarcinoma
Stage
Locally advanced 70 NA 55
Metastatic 30 45
Blood chemistry
B-hemoglobin (g/dL) 13.4 (±1.5) 11.9 (±0.9) 12.6 (±1.5)
ALAT (U/L) 45.2 (±21.8) 59.7 (±42.9) 71.2 (±59.6)
LD (mg/dL) 151.4 (±27.6) 209.6 (±46.0) 177.7 (±49.4)
Bilirubin (μmol/L) 14.5 (±8.46) 7.3 (±4.0) 37.3 (±66.0)
CA 125 (U/mL) 54.1 (±39.6) 62 (±60.1) 90.0 (±100.5)
CA19-9 (U/mL)a 248.5 (±380.8) 117.1 (±202.9) NA
Comments:
Obligatory lab values for chemotherapy inclusion: B-Hemoglobin N10, Neutrophils
(polymorphoneuclear leukocytes) N3.5, Platelets N150, Bilirubin N75.
a One sonoporation treatedpatient exhibited abnormally highCA19-9 values at 4608U/
mL hence not included in average CA19-9 values.
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dire need for novel therapeutic interventions.
Gemcitabine has been the standard chemotherapeutic used in
recent years and the most effective single agent. Compared to 5-
ﬂuorouracil, gemcitabine extends the survival by approximately one
month whilst also improving clinical symptoms [6]. Recently,
FOLFIRINOX (bolus and infusion of 5-ﬂuorouracil, leucovorin,
irinotecan, and oxaliplatin) emerged as a new chemotherapeutic option
for patients with metastatic pancreatic cancer and an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0–1. For this cohort
of patients FOLFIRINOX is now the reference treatment. However,
owing to the demonstrable toxicities and side effects of this therapy,
gemcitabine is still the standard of care in patients with poor perfor-
mance status or contraindication to FOLFIRINOX [7]. Furthermore, the
combination of nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
and gemcitabine provides another new therapeutic option resulting
with improved median survival of 1.8 months, compared to
gemcitabine alone [8]. Despite these novel interventions, the reported
increases in survival areminimal andwe continue ourwait for a therapy
that will impact survival, provide a bridge to reductive surgery and ulti-
mately cure PDAC.
Diagnostic ultrasound (US) imaging has been used in the clinic for N
50 years [9,10], with detection of pancreatic lesions dating back to the
late 1960s [11]. Over the past 30 years, the use of ultrasound to detect
PDAC has signiﬁcantly increased [11–13]. Contrast-enhanced ultra-
sound uses stabilised gas microbubbles (MBs) to enhance the signal-
to-noise ratio of the vasculature and allows clinicians to better visualise
tissue perfusion. Twenty years ago, researchers discover that upon ap-
plication of ultrasound these microbubbles volumetrically oscillate. If
these oscillating microbubbles were in the vicinity of cells, small pores
could be formed increasing the uptake of macromolecules signiﬁcantly
[14–16]. Henceforth, the use of ultrasound and microbubbles to invoke
biomechanical effects that increase the permeability of the vascular bar-
rier and/or the extravasation of drug in a speciﬁc location is now com-
monly known as “sonoporation”.
Numerous researchers have shown in vitro and in vivo that
sonoporation is a viable technique to improve drug delivery and im-
prove therapeutic efﬁcacy in various cell lines derived from pharyngeal
[17], glioma [18], prostate [19,20], melanoma [21], and pancreatic can-
cer [22]. Sonoporation has also been used to open the blood brain barri-
er [23,24]. In general, sonoporation research is split into two camps: A)
high-intensity, i.e., using inertial cavitation [9,25–27] and/or taking ad-
vantage of the thermal effects [28,29], and B) low-intensity, i.e., using
stable cavitation [30,31] and non-thermal effects [32–34].
The use of high-intensity ultrasound without MB has previously
been evaluated clinically and shown considerable success for pain ther-
apy [35,36], ablation of breast ﬁbroadenomas [37], opening the blood-
brain barrier [38] and treatment of pancreatic adenocarcinoma [39].
Nevertheless, to our knowledge, there has been no clinical trial evaluat-
ing the efﬁcacy of low-intensity ultrasound in combination with
microbubbles to improve the chemotherapeutic efﬁcacy in patients
with PDAC.
We have previously demonstrated in vitro and preclinically in an
orthotopic model of PDAC, enhanced treatment effects of gemcitabine
with concurrent exposure to SonoVue® MB and US at low acoustic in-
tensities [40]. Based on these preclinical results we initiated an open
label phase I, single centre, safety evaluation study in PDAC patients
by combining an ultrasound contrast agent and gemcitabine under son-
ication at clinical diagnostic conditions.
The primary objective of this study was to evaluate the safety and
potential toxicity of gemcitabine combined with ultrasound contrast
agent under ultrasound treatment in inoperable pancreatic cancer pa-
tients. The secondary objective was to evaluate a novel image-guided
microbubble-based therapy, based on commercially available technolo-
gy, towards improving chemotherapeutic efﬁcacy, preserving patient
performance status and prolonging survival.2. Material and methods
2.1. Subjects
Over a 23-month period (January 2012–November 2013), we re-
cruited ten consecutive voluntary patients with inoperable pancreatic
cancer (ICD-10 C25.0–3) at Haukeland University Hospital. All had his-
tologically veriﬁed, locally advanced (non-resectable Stage III) or meta-
static (Stage IV) pancreatic adenocarcinoma. Needle biopsies were
obtained either from the primary tumour or from a metastatic lesion.
The tissuewas processed in the diagnostic pathology laboratory accord-
ing to standard routines (formalin-ﬁxation, parafﬁn-embedment, stain-
ing with hematoxylin and eosin). The histology was evaluated by a
senior pathologist with special competence in gastrointestinal patholo-
gy. Patients were ambulatory with an Eastern Cooperative Oncology
Group (ECOG) performance status 0–1 (Table 1). Patients had to meet
the standard criteria at our hospital for treatment with gemcitabine
and no known intolerance to gemcitabine or SonoVue® (Bracco Imag-
ing Scandinavia AB, Oslo, Norway) ultrasound contrast agent [45].
Historical data from PDAC patients undergoing equal gemcitabine
treatment following the same inclusion and exclusion criteria, between
2009 and 2011 atHaukelandUniversityHospital, were used for compar-
ison of treatment tolerance, safety, and overall survival. The only differ-
ence in treatment between the historical control group and our treated
group was the addition of ultrasound and microbubbles following che-
motherapeutic infusion. Gemcitabine was considered the standard of
care for the treatment time period of the control patients and through-
out this clinical study.
2.2. Chemotherapeutic and microbubble dosage
Two experienced oncologists, not participating in the study,were re-
sponsible for the chemotherapeutic treatment. The only divergence
from normal administration practice was relocation to the research
unit. We used the standard recommended treatment protocol of
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[45]. Speciﬁcally, an initial phase of intravenous gemcitabine infusion
was administered at a frequency of one cycle per week for seven
weeks followed by a one-week pause. Subsequent cycles of infusions
were given once weekly for 3 consecutive weeks out of every 4 weeks.
Treatment pauses or any dose adjustments were administered accord-
ing to standard guidelines [43,45]. Chemotherapy was continued as
long as the treatment was beneﬁcial [46]. The patients were monitored
according to the requirements for Phase I studies [47].
Maximum plasma concentration of gemcitabine is achieved after
30min atwhich point sonoporationwith Sonovue®was initiated to en-
sure maximal possible tumour exposures [48]. Clinically approved
SonoVue® ultrasound contrast agent was used as the microbubble for
sonoporation [49]. Ethical approval limited treatment to the use of a sin-
gle vial of microbubbles, paralleling traditional imaging protocols. Due
to the acoustic emission limitations of the clinical diagnostic scanner
(c.f., Section 2.4) we chose to maximise the treatment time to achieve
the longest active sonoporation time (i.e., time when ultrasound
waves and microbubbles were present). The expected in-vivo life time
of microbubbles was 4–5 min, hence we chose to inject boluses every
3.5 min to ensure microbubbles were present continuously throughout
the whole treatment. Previous experience [50] showed that we were
able to detect microbubble using non-linear ultrasound imaging using
0.5 ml boluses [51]. Due to these requirements, microbubble dosage re-
sults in 0.5 ml of SonoVue® followed by 5-ml saline every 3.5 min, im-
mediately after the end of the intravenous infusion of gemcitabine [43].
A complete vial was used in 31.5 min. The total dose of contrast agent
used throughout each treatment was within standard clinical practice
[52].
2.3. Ultrasound scanner conﬁguration
In our previous studies we determined that sonoporation had a sig-
niﬁcant therapeutic effect when using long pulse durations, speciﬁcally
40 μs pulses every 100 μs (i.e., a duty cycle of 40%) [41,44]. This resulted
in minimal acoustic energy deposition within FDA and IEC guidelines
and maximum therapeutic efﬁcacy [53,54]. In this clinical study, an
unmodiﬁed clinical diagnostic ultrasound scanner (LOGIQ 9, GE
Healthcare, Waukesha, WI) in combination with a 4C curvilinear
probe (GE Healthcare) was used to apply the therapeutic ultrasound.
Unfortunately, it is not possible to generate such long duty cycles with
an unmodiﬁed clinical diagnostic machine, due to technical limitations.
In addition, such long duty cycles would severely degrade the image
resolution. Hence, we attempted to maximise the ultrasonic duty cycle
emitted by the clinical machine, whilst keeping linear waves, to avoid
bubble destruction and energy deposition at higher harmonics.
In order to determine the ideal settings, the machine was
characterised and calibrated in a bespoke, automated, 3-axis ultrasound
characterisation chamberﬁlledwithﬁltered, degassed, deionisedwater.
To waterproof the probe prior to submersion, the transmission surface
was covered in AQUASONIC® ultrasound transmission gel (Parker Lab-
oratories, Fairﬁeld, NJ), and subsequently covered using a latex ultra-
sound probe cover (Sheathing Technologies, Inc., Morgan Hill, CA).
The probe was locked in place and a range of acoustic emission condi-
tions were evaluated with the aim of reaching the longest duty cycle
with linear waves (i.e., minimum amount of harmonics) at a de-rated
MI of 0.2. The ultrasound emission conditions were characterised fol-
lowing FDA and IEC ultrasound guidelines [53,54]. To achieve the max-
imum pulse repetition rate the packet size was maximized. Whilst this
reduced the frame rate substantially, it resulted in increasing the pulse
repetition signiﬁcantly higher than possible with a frame rate increase
alone. Knowing that each patient would have a different tumour
depth and size, various focal and image depths were calibrated to en-
sure all patients were treated with identical conditions. The ultrasound
scanner conﬁguration was programmed to maximise the duty cycle,
with short broadband linear pulse in order excite asmanymicrobubblesas possible for the longest period possible. These acoustic emission con-
ditionswere considered optimal in relation to the limitations of the clin-
ical ultrasound system emission conﬁguration conditions. The device
optimized acoustic conditions resulted in a derated MI of 0.2
(0.27 MPa peak-negative pressure), a 0.3% duty cycle with a center
emission frequency of 1.9MHz, and a spatial-peak temporal-average in-
tensity of 0.25 mW/(cm) [2]. Speciﬁcally, the beamformed ultrasound
bursts consisted of 4 cycles (2.1 μs) every 21 ms, i.e., a transmission
duty cycle of 1%. Following the completion of the 12 ultrasound packet
transmissions, therewas a transmission pause allowing for echo capture
and image reconstruction resulting in an overall duty cycle of 0.3%. The
center frequency of 1.9MHzwas ideal as it was close to the natural res-
onance of the SonoVue®microbubbles [55]. At an MI of 0.2, only stable
cavitation was expected to be induced throughout treatment. These
acoustic emission conditions resulted in a 1-cm thick treatment slice
based on a−3 dB contour [43].
To make sure that treatment only occurred at the target, i.e., the
tumour, the image plane and non-linear contrast region of interest
(ROI) was limited to the tumour area +1 cm surrounding area. We
avoided treating any liver or bowel area. The acoustic focal depth
was placed at the centre of the tumour. The expected treatment
height, based on a −3 dB contour was 3 cm above and below the
acoustic focus depth.
This image-guided therapy model is based on the expectation that
treatment only occurswhere the ultrasound andmicrobubbles are pres-
ent, i.e., what is being imaged.
The ultrasound probe was re-calibrated every six months to
ensure acoustic consistency. The exact acoustic conditions and the
ultrasound ﬁeld map are thoroughly described in our previous pub-
lication [43].2.4. Transabdominal ultrasound
Routine abdominal US imaging [56] was performed during the
last 10 min (T = 20 min) of chemotherapeutic delivery using the
same LOGIQ 9 clinical diagnostic ultrasound scanner as for treat-
ment. The ultrasound probe was attached to a ball-head mount
allowing for initial free-hand scanning. Once in the optimal position
for treating the tumour, with the largest diameter targeted, the ball-
head mount was locked and the ultrasound probe was kept in this
position till completion of the treatment [43] (c.f., Fig. 1). The opti-
mal treatment position of the 4C clinical diagnostic ultrasound
probe to ensure a clear acoustic path to the tumour without any ob-
structions such as stomach and bowel air varied per patient. This was
achieved by following established diagnostic protocols for imaging
the pancreas [56,57]. In general, the probe was positioned in the epi-
gastric region with the acoustic propagation path pointing towards
the pancreatic tumour. The azimuth and elevation of the probe was
adjusted to avoid any air pockets and liver tissue. The patients
were allowed to lie in their most comfortable position prior to locat-
ing the tumour and locking the transducer in place. The patients
were consulted if any discomfort was felt, and pressure adjustments
were made if necessary. The large vasculature near the primary tu-
mour was visualized using non-linear contrast mode in order to val-
idate that microbubbles were being sonicated near the target
tumour. Patient breathing allowed for passive scanning of the tu-
mour, as with each breath the tumour would move through the
acoustic ﬁeld. The amount of passive scanning varied per patient
breathing volume. Breathing based passive scanning ranged be-
tween 1 and 3 cm at the tumour level.
The total duration of combined ultrasound and microbubble treat-
ment was 31.5 min. Fig. 1 shows the experimental setup used to com-
bine chemotherapy, ultrasound, and microbubbles. Panel A shows the
time course of each treatment cycle whilst Panel B shows a photograph
of the ultrasound positioned to treat the tumour.
Fig. 1. (A) Treatment procedure ﬂow chart with timings of chemotherapeutics, ultrasound exposure, and microbubble infusion. Using the current protocol, the treatment duration was
61.5 min. The ﬁrst 30 min were reserved for chemotherapeutic infusion and the last 31.5 min were reserved for ultrasound and microbubble treatment. Abdominal imaging was
performed for the last 10 min of infusion. Every 3.5 min, 0.5 ml of SonoVue® microbubbles were injected. (B) Photograph of patient with PDAC undergoing treatment using a clinically
available diagnostic scanner. The ultrasound probe was locked in position using a mechanical arm targeted at the primary tumour for the full 31.5 min of ultrasound and microbubble
treatment.
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Analytical methods for pharmacokinetic (PK) evaluations were de-
veloped in parallel to the clinical study [58]. Whole blood samples
were collected sequentially into prechilled heparinized tubes at the fol-
lowing time-points: T = 0, 30, 60, 120, 180 and 240 min. Tubes were
spiked with the cytidine deaminase inhibitor tetrahydrouridine to pre-
vent deamination of gemcitabine to dFdU [58]. Plasma andmononucle-
ar cells were separated from whole blood as described previously.
Concentrations of gemcitabine and dFdU were measured in plasma
using in-house LC-MS/MS methods [58].2.6. Monitoring
All patients underwent dual-phase computed tomography (CT) im-
aging ≤3 weeks before study inclusion. Routine abdominal CT was per-
formed every 8th week where maximum tumour diameter was
quantiﬁed by independent radiologists. Tumour size and development
was characterised according to the Response Evaluation Criteria in
Solid Tumours (RECIST). Positron emission tomography (PET) imaging
with F-18-ﬂuoro-deoxyglucose (FDG)was performed prior to the treat-
ment to determine if metastases were present.
Assessment of clinical state during the treatment also included an
evaluation of the clinical beneﬁt response and if surgical resection
could be performed [46,59]. ECOG performance status was used as a
proxy to monitor the effectiveness of the combined treatment. The
ECOG scale describes patients' level of functioning in terms of theirability to care for themselves, daily activity, and physical ability [46].
An ECOG grade of 0 indicates a patient who is fully active and able to
carry on all pre-disease performance without restriction. An ECOG
grade of 1 indicates that a patient is restricted in physical strenuous ac-
tivity but ambulatory and able to carry out work of a light or sedentary
nature, e.g., light housework, ofﬁcework. An ECOGgrade of 2 indicates a
patient is ambulatory and capable of all self-care but unable to carry out
any work activities. The patient is up and about N50% of waking hours.
An ECOG grade of 3 indicates a patient capable of limited self-care and
conﬁded to bed or chair N50% of waking hours. Hence, the longer a pa-
tient stayed below an ECOG grade of 3, themore effective the treatment
was considered indicating an extended period of well-being. When a
patient reaches an ECOG grade of 3, they are no-longer able to undergo
gemcitabine chemotherapy.
Select patients also underwent diagnostic contrast-enhanced ultra-
sound following established clinical procedures [60]. Blood analysis
was performed to evaluate if there was any acute toxicity.
2.7. Statistical analysis
The results are expressed asmean values± SD, unless otherwise in-
dicated. Continuous data was analysed using t-tests, or Mann-Whitney
tests if data were not normally distributed. Gehan-Breslow-Wilcoxon
test and Log-rank (Mantel-Cox) test were used to compare survival.
Variance is expressed through 95% conﬁdence intervals. p b 0.05 was
considered statistical signiﬁcant. Patients removed from the study due
to improvement were considered as intention to treat in the survival
statistical analysis.
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3.1. Tumour targeting
The established guidelines for imaging the pancreas [56,57] allowed
us to target the primary PDAC tumour, independent of tumour depth
and size. Fig. 2 shows four representative ultrasound images of the
PDAC tumours from our treated patient cohort captured prior to
switching the diagnostic ultrasound scanner settings to “treatment
mode”. In these images tumour depths ranges from 3.1 cm to 8.9 cm in-
dicating that shallow or deep tumour did not inhibit tumour visualisa-
tion or targeting.
3.2. Toxicity evaluation
The direct parameters used to evaluate the toxicity of our treatment
were clinical parameters including vital signs, ECG and blood chemistry.
Overall, all data indicated that gemcitabine in combination with US did
not induce any unexpected deviation or additional toxicities than che-
motherapy alone.
One patientwas hospitalised for a serious adverse event (SAE) unre-
lated to protocol therapy. Four SAEs occurred during protocol therapy.
Two patients had symptoms indicating biliary obstruction and necessi-
tated hospitalisation and rescheduling of the treatment. One was treat-
ed for pneumonia and one had fever due to cholangitis. The most
frequent possibly treatment-related toxicities i.e., adverse events (AE)
were abdominal pain (n=9), nausea (n=7), fever (n=6), neutrope-
nia (n=6), and fatigue (n=6) as described in Fig. 3. These eventswere
registered as possibly related to protocol therapy. Since all the reportedFig. 2. Representative ultrasound images showing the PDAC tumour in four of the ultrasound an
green dotted lines. The ultrasound transducer was positioned to ensure no obstructions of the a
patient and treatment. Distance 1 and 2 indicate the tumour width and height respectively. Vatoxicities are expected side effects of gemcitabine, they were evaluated
as gemcitabine related. All other AE were probably related to progres-
sion of underlying disease. There were no treatment-related deaths.
3.3. Blood biochemistry
No additional toxicity was observed. Blood values changed as ex-
pected. CA 19-9 and CA 125 levels decreased in 5 out of 8 patients mea-
sured, and 7 of the 10 patients, respectively.
When evaluating the levels of cancer marker CA 125 we observed a
decline following combined treatment. A total of four out of ten patients
went from elevated to normal counts and only a single patient went
from normal to elevated counts. Whilst fewer measurements were
made in the CA 19-9 counts a similar trend was also observed where
three patientswent fromelevated counts to normal counts,ﬁve patients
showed a decrease, two patients showed an increase, and only a single
patient went from normal to elevated counts. No correlation between
tumour size change and cancer marker count was observed (Supple-
mental Fig. 1).
Bilirubin, LD, ALAT and other liver parameters were in line with the
expected variation under gemcitabine treatment. Thesewere all consid-
ered to be normal blood biochemistry changes as expected from chemo-
therapy and disease course.
3.4. Clinical beneﬁt and response assessment
The followingmethodswere applied to evaluate the responses in the
ten patients: RECIST, tumour size, ECOG grade and treatment cycles
[59,61].dmicrobubble treated patients. Tumour height andwidth are indicated by the yellow and
coustical beam path to the tumour. This resulted in a unique ultrasound probe position per
lue D indicated the tumour centroid depth.
Fig. 3. Percentage of patients with PDAC treated with sonoporation that experienced a given adverse event. This graph shows all the adverse events experienced by all patients regardless
of severity grade, or direct correlation to the treatment. All adverse events were already associated with gemcitabine treatment alone, indicating that addition of ultrasound and
microbubbles did not induce or increase the frequency of new adverse events.
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ularly evaluated by the Dept. of Oncology for FOLFIRINOX treatment or
consolidative radiation therapy and surgery. After 12 treatment cycles,
one patient was down-staged from 8.6 cm to 4.2 cm in tumour size
and thereby became available for potentially curative therapy. She
was removed from the clinical trial and underwent radiation therapy
and subsequent pancreatectomy. Five patients exhibited partial re-
sponses as evidenced by reduction in tumour diameter. As a result,
they were offered either consolidative radiation therapy or FOLFIRINOX
treatment.
Fig. 4 shows the effect of our combined treatment on the tumour
size. The green lines indicate the patient tumour size recession or stabi-
lization from the start to the end of the treatment, whereas the red lines
indicate tumour size increase. When the line ends, this indicates that
the patient was removed from the clinical trial.
An average of 13.8 ± 5.6 and median 12.5 (range 5–26) treatment
cycles of protocol therapy were delivered per patient. In comparison,
our historical control group treated with the same chemotherapeutic
protocol of gemcitabine alone received an average of 8.3 ± 6.0 andme-
dian 7 (range 1–28) treatment cycles (p=0.008). Fig. 5A shows awhis-
ker plot depicting the number and range of treatment cycles.
Fig. 5B shows the survival curve of the combined treatment group
compared to the historical control group. The number of treatment cy-
cles and days of survival in our patient group are summarised inFig. 4. Maximum tumour size as function of time for all ten patients with inoperable
pancreatic adenocarcinoma. Green lines indicate tumour size recession or stabilization.
Red/orange or grey lines indicate tumour size increase. Colour gradient indicates linear
regression ﬁt of tumour growth gradient (lighter = shallower). Five out of ten patients
(50%) showed tumour size reduction during treatment. A reduction in tumour size may
allow for surgical resection; the only current curative option. The star (*) indicates
which patients showed tumour size reduction and were evaluated for consolidative
radiation therapy or FOLFIRINOX treatment.Table 2. Both Gehan-Breslow-Wilcoxon test and Log-rank (Mantel-
Cox) test showed that the survival was signiﬁcantly different with
p= 0.0043 and p= 0.011, respectively.
3.5. Gemcitabine pharmacokinetics
Concentration proﬁles of gemcitabine and dFdU in plasma samples
were in accordance with previous studies of gemcitabine-infusions of
800–1000 mg/m2 administered to breast, lung, pancreatic and patients
with various other solid tumours [48,62]. This demonstrates that the
combination regimen did not seem to alter the systemic pharmacoki-
netics of gemcitabine. A representative concentration proﬁle from one
of the patients is shown in Supplemental Fig. 2.
4. Discussion
To our knowledge, this is the ﬁrst human trial evaluating the use of
low intensity ultrasound and microbubbles to treat cancer. All previous
studies have only been performed in vitro or pre-clinically. Clinical stud-
ies using ultrasound for therapy have been focused on high-intensity ul-
trasound without microbubbles, or for pain treatment. Hence the effect
of low intensity sonoporation therapy for PDAC in humans is unknown
[44,63–65].
In our previous study [43], we presented the experimental protocol
focusing on the technical aspects of implementing low-intensity
sonoporation using a clinical diagnostic ultrasound scanner. We also
presented pilot results of ﬁve patients brieﬂy discussing the number of
cycles and tumour sizes. In the currentworkwe present the ﬁnal results
and clinical data of all 10 patients, including a comparison of overall sur-
vival. In addition,we provide a toxicity report regarding the safety of the
study following 138 treatment cycles.
The primary aim of this Phase I study was to evaluate the safety and
potential toxicity, when combing microbubbles, ultrasound, and a che-
motherapeutic agent in patients with PDAC. Hence, in this clinical trial
we only evaluated a total of ten patients, as required by the NMA. Over-
all, all data clearly indicated that this combination did not induce any
additional toxicities.
4.1. Cancer markers
These results indicate that chemotherapy in combination with
microbubbles andultrasoundmayhave a positive impact on tumour de-
velopment. It iswell known that there are correlations between CA 19-9
decline and both overall survival and time to treatment failure in pa-
tients treated with gemcitabine alone [66]. The limited number of pa-
tients in our Phase-I-trial does not allow us to make any further
conclusions.
Fig. 5. (A) Whisker plot comparing the number of treatment cycles undergone in patients with pancreatic adenocarcinoma. Patients treated with sonoporation showed a statistically
signiﬁcant increase in number of treatment cycles (p= 0.008, unpaired t-test) indicating inhibited tumour progression and extended period of well-being (B) Survival plot comparing
patients treated with ultrasound, microbubbles, and gemcitabine vs gemcitabine alone. The survival curve indicated that the combined treatment group had near twice as high median
survival compared to treatment with gemcitabine alone; from a median of 8.9 months to 17.6 months (p = 0.011, Log Rank test).
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In our present work, we present all adverse events experienced
by the patients independent of grade and severity (Fig. 3). This also
includes adverse events due to the actual malignancy, or personal
experiences. Other clinical studies typically only register adverse
events that can be directly correlated to the treatment itself, with oc-
currences above 10% and grades ≥3 [45]. As adverse events are rarely
registered clinically, we were unable to directly compare with our
historical group. To aid comparison we have compared to values
available in literature (c.f., Supplemental Fig. 3). In this Figure, we
observe a 40% difference of abdominal pain. The primary symptoms
of pancreatic cancer are abdominal pain and weight loss [67], as a re-
sult this symptom is rarely recorded. Nine out of our ten patients ex-
hibited abdominal pain prior to treatment, hence we do not attribute
this adverse event as treatment related. In contrast, in studies where
weight loss was recorded, it was observed in nearly all patients. In
our treated patient cohort, only 20% (2 patients) exhibited weight
loss. Throughout this study all AE had already been previously asso-
ciated with gemcitabine chemotherapy alone. This strongly suggests
that there is no additional toxicity when combining ultrasound and
microbubbles with gemcitabine chemotherapy.4.3. Overall survival and well being
When the patients' health deteriorates, and their ECOG status rises
above 2, they are no longer able to undergo therapy. Hence, number
of treatment cycles indirectly represents the physical well-being of the
patients. Our clinical trial group was able to undergo 66% more cycles
than the historical control group. It is important to note that the analysis
of treatment cycles is biased against the sonoporation group as four outTable 2
Number of cycles and days survival as of diagnosis for patients with pancreatic cancer
treated with ultrasound, microbubbles, and gemcitabine. The number of treatment cycles
ranged from 5 to 26 cycles whereas survival ranged from 207 to over 1333 days.
Patient Number of treatment cycles Days survival
P1 26 443
P2a 11 207
P3 10 774
P4 16 513
P5 16 859
P6a 11 412
P7a 12 1333
P8a 18 543
P9 5 464
P10a 13 865
Average 13.8 641
Median 12.5 528
SD 5.7 322
a Patients removed from the study due to improvement.of ten patients were removed from the study due to reduction of the tu-
mour size. If these patients had continued treatment, the number of
treatment cycles would be higher. This suggests that chemotherapy in
combination with ultrasound and microbubbles may prolong the phys-
ical health and ambulatory status of patients with pancreatic cancer.
Due to the study design, our data may not be directly comparable to
the historical control cohort; hence these results should be interpreted
with caution.
When evaluating survival, our results showed a mean survival of
21.4 months andmedian survival of 17.6 months. This was signiﬁcantly
longer than our historical control group (8.9 months) and literature
values (6.7months) [5].Whilst these results should be interpreted care-
fully, we argue that chemotherapy in combination with ultrasound and
microbubbles probably increases survival in patients with pancreatic
cancer.
4.4. Other chemotherapeutic options
Whilst gemcitabine is no longer considered at the forefront of che-
motherapeutic treatment for PDAC, it was the ﬁrst choice treatment
when this clinical trial was initiated [68]. Other drugs and drug-combi-
nations such as FOLFIRINOX and Gemcitabine+ nab-Paclitaxel are now
considered state-of-the-art [7,8]. As this trial was initiated using
Gemcitabine we could not modify the protocol when other drugs and
drug combinations reached the forefront of PDAC chemotherapeutic
treatment. Gemcitabine is still commonly usedworldwide for the treat-
ment of PDAC, hence this protocolmay allow for easier implementation.
When we compare median survivals of these patient groups from
literature we see that FOLFIRINOX results in median survival of 11.7
months while gemcitabine + nab-Paclitaxel give a median survival of
12.2 months [69]. The observed median survival in our study far
surpassed both these values using a less effective drug (Graphical Ab-
stract). As sonoporation is not limited to any speciﬁc drug, inducing
sonoporation with a more effective chemotherapeutic may further im-
prove the therapeutic efﬁcacy. In the case of combined chemotherapeu-
tics, sonoporation could either be induced during or after infusion of all
drugs, or at a time point where all chemotherapeutics are in the
bloodstream.
4.5. Tumour perfusion
PDAC is well known to be a hypovascular tumour [70], meaning it
has less perfusion than the tissue surrounding it. This is falsely correlat-
ed to no perfusion.Nevertheless, in the clinicalﬁeld it iswell known that
PDAC still exhibits perfusion. An example of such hypovascular perfu-
sion can be seen the Supplemental video 1 and Fig. 6. Fig. 6 shows a B-
Mode image, contrast-enhanced image, and a perfusion curve of the
aorta, healthy pancreatic tissue and the primary PDAC tumour.
Microbubbles can be clearly distinguished in the primary PDAC tumour
when comparing the primary PDAC tumour area in Fig. 6 A vs. B. The
perfusion curve Fig. 6C, depicts non-linear contrast echo amplitude as
179G. Dimcevski et al. / Journal of Controlled Release 243 (2016) 172–181a function of time for three regions of interest (ROI). The results validate
that microbubbles enter the PDAC tumour. At T= 0, i.e., the time of in-
jection, no microbubbles are present (i.e,−68 dB is the base line). At
around 25 s the aorta is the ﬁrst ROI to reachmaximumperfusion, as ex-
pected. The pancreas reachesmaximumperfusion at around27 s,whilst
the PDAC tumour reachesmaximumperfusion at around 32 s. The aorta
shows the highest nonlinear echo amplitude, followed by the pancreatic
tissue. The PDAC has the lowest nonlinear echo amplitude whilst still
being 26 dB higher than the baseline, but only 5–10 dB lower than the
pancreas. This indicates the tumour has lower perfusion than the sur-
rounding tissue, yet is sufﬁciently perfused to allow microbubbles to
enter.
It is important to note that our historical control group treated with
gemcitabine alone has amedian survival of 8.9months, which is slightly
higher than that previously reported in literature (6.7 months) [3,5,71]
indicating that our historical control group was not negatively biased.
4.6. Potential mechanisms of sonoporation in vivo
In vitro, sonoporation is typically evaluated on a cell monolayer
allowing direct contact between the target cell line and microbubbles.
In vivo, the microbubbles ﬂow through the vasculature and capillaries
allowing direct contact only with endothelial cells, resulting inFig. 6. Contrast-enhanced ultrasound of the PDAC tumour in Patient 7. Panel A: B-mode image
PDAC tumour and aorta have been labeled. Microbubbles can be clearly distinguished in the
non-linear echo amplitude as a function of time for the three regions of interest: Aorta (yellow
time-to-peak and lower perfusion than both the aorta and pancreas, yet is still adequately per
57 s after microbubbles injection (c.f.,white arrows in Panel C).enhanced uptake only by these cells or, in some cases, in deeper cell
layers [72,73]. We believe that the therapeutic efﬁcacy observed in
this Phase I clinical trial cannot only be attributed to the potential in-
crease of gemcitabine uptake in the endothelial cell walls. The interac-
tion between the vascular barrier and microbubbles may result in
increased fenestration size allowing deeper drug penetration [74]. It is
also known that ultrasound in combination with microbubbles can in-
crease intracellular stress signalling [75]. This increased stress, in combi-
nation with the chemotherapeutic may result in enhanced drug
sensitivity. Nevertheless, further work needs to be performed, pre-clin-
ically and clinically to ascertain the true mechanisms behind the im-
proved therapeutic efﬁcacy.
4.7. Limitations
Whilst all these results show great promise, we cannot make global
assertions on the efﬁcacy of ultrasound-enhanced chemotherapy based
on this study. To further understand and validate these results it is par-
amount to perform mechanistic experimental studies and examine a
larger patient cohort in a prospective randomized controlled Phase II
trial.
The tumour size reduction was measured using the maximum tu-
mour diameter. Whilst this method gives a representative overview of. Panel B: Contrast-Enhanced image using SonoVue®microbubbles. Pancreatic tissue, the
PDAC tumour when comparing to the B-Mode image. Panel C: Perfusion curve depicting
), pancreatic tissue (red) and PDAC tumour (cyan). The PDAC tumour exhibits a longer
fused for microbubbles to enter. Panels A and B are freeze frames of late phase perfusion,
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change of the tumour. In our opinion, future work should address the
treatment effect on the tumour volume and not only the maximal
diameter.
The primary limitations of this study are that only a single 2D slice of
the tumour was treated. Using a 3D ultrasound probewith further opti-
mized acoustic conditions and modifying the microbubble type and
concentration may improve the therapeutic efﬁcacy [44].
The ultrasound emission conditions used here were severely limited
by the clinical diagnostic scanner. In previous studies, longer duty cycles
have shown to have a better therapeutic effect than short duty cycles
[76]. Future work should aim to determine the ultrasound conditions
that induce the highest therapeutic effect and to allow implementation
of such conditions in the clinic.
There is currently no consensus on what is considered an ideal
microbubble dose. At high dosages, the microbubbles may interact
more with each other than the cells due to secondary Bjerknes forces
[42], whereas at low concentrations, there may not be enough
microbubbles to interact with the cells. Future work should evaluate
and optimise the microbubble type and dosage.
In theﬁeld of sonoporation, it is typically assumed that the enhanced
effect is due to the increase in local drug concentrations. In ourwork,we
did not evaluate if the local drug concentrationwas increased and if this
could be the reason for the enhanced effect. Future work should evalu-
ate if there is an increase in local drug concentration, or if the improved
therapeutic efﬁcacy is due to increase or decrease in perfusion, or other
intracellular responses.
5. Conclusion
In conclusion, our study indicated that chemotherapy in combina-
tion with ultrasound and microbubbles seems to be safe. No additional
toxicity was observed when compared to chemotherapy alone. In our
patient cohort, sonoporation has the additional beneﬁt of improving
the number of treatment cycles the patients were able to undergo and
correspondingly extending the period of well-being. Signiﬁcantly in-
creased survival was also observed compared to a historical cohort of
patients. Acknowledging the small treatment group with sub-optimal
treatment conditions in this study, a larger study with improved acous-
tic conditions and microbubble delivery is essential to improve our un-
derstanding and validating our results. Nevertheless, in our opinion
these novel results show great promise for ultrasound andmicrobubble
enhanced therapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2016.10.007.
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